BioNTech reported a disappointing quarter, moving from a €259.5 million profit a year ago to a net loss of €305 million. The company posted a per-share loss of €1.25 on revenue of €907.4 million, which was much worse than analysts’ forecasts of a €0.45 loss on €768.3 million in revenue.
The company’s outlook added to the disappointment. Management expects full-year 2026 revenue between €2 billion and €2.3 billion, which is well below the roughly €2.75 billion analysts had predicted. This gap suggests there are ongoing challenges, not just a one-time setback.
Shares dropped about 17% in premarket trading, putting the stock on track for its biggest one-day decline in over four years.
The worsening financial situation comes as the company faces a major leadership change. The co-founders, who are also the chief executive and chief medical officer and started BioNTech in 2008, announced they will leave by the end of the year to start a new biotech company. The supervisory board has begun looking for their replacements. BioNTech plans to give some rights and mRNA technologies to the new company in return for a minority stake, milestone payments, and royalties.
The leadership changes make an already tough situation even harder. Revenue from BioNTech’s main product, developed in partnership, has been declining since the peak of the pandemic. Management expects this decline to continue in both Europe and the U.S. through 2026. Meanwhile, a separate cancer partnership is expected to bring in about the same revenue as last year. In the United States, where mRNA technology — the foundation of BioNTech’s vaccine and cancer immunotherapy pipeline — has come under heightened scrutiny following a change in federal health leadership. The current administration has adopted a skeptical posture toward mRNA-based therapeutics, creating uncertainty around the regulatory pathway for next-generation products.
Prior to Tuesday’s selloff, BioNTech’s U.S.-listed shares had only made small gains in 2026, falling far behind the strong recoveries seen at other vaccine makers.
Featured Courses
Recent news
Microsoft Heads for Worst Quarter Since 2008
Microsoft is facing its largest quarterly decline since 2008. Shares are down about 25% this quarter, making it the weakest Magnificent Seven member by a wide margin. The group is down roughly 14%. The stock fell another 1.7% after Friday’s open, marking a fourth consecutive day of losses. Two primary risks are driving Microsoft’s selloff […]
Unity Stock Surges 13% on AI-Focused Restructuring
Unity Software shares jumped 13% to $19.39 in premarket trading on Friday, briefly beating the S&P 500. Investors liked the company’s decision to cut weak assets and focus on AI-powered revenue growth. The main reasons were a strong first-quarter revenue outlook and Unity’s plan to shut down its ironSource Ads Network on April 30 and […]
NVIDIA Cheaper Than the S&P 500: Is This the Floor?
NVIDIA’s stock is now at its lowest valuation relative to the broader market in over ten years. This creates a rare buying opportunity for investors, as bargain hunters and long-term investors may find the historically low valuation appealing despite ongoing pressure on AI-related technology stocks. The main thesis is that NVIDIA is a unique investment […]
Trade with fewer limits
Day trade with fewer limits at fast speed. Buy stocks and ETFs at low fees.